在接受含或不含曲妥珠单抗的卡铂和紫杉醇无蒽环类新辅助化疗后，三阴性、HER2阳性和激素受体阳性乳腺癌的病理完全缓解率。
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
作者信息
Shinde Arvind M, Zhai Jing, Yu Kim Wai, Frankel Paul, Yim John H, Luu Thehang, Kruper Laura, Vito Courtney, Shaw Sally, Vora Nayana L, Kirschenbaum Michele, Somlo George
机构信息
Department of Medical Oncology and Therapeutic Research, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
Department of Pathology, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
出版信息
Breast. 2015 Feb;24(1):18-23. doi: 10.1016/j.breast.2014.10.008. Epub 2014 Nov 20.
Abstract
BACKGROUND
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates.
METHODS
Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed.
RESULTS
Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR.
CONCLUSIONS
Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.
摘要
背景
新辅助化疗（NCT）后的病理完全缓解（pCR）被认为是生存改善的替代指标。含铂新辅助化疗，特别是在人表皮生长因子受体2（HER2）阳性和三阴性乳腺癌（TNBC）患者中，可能会提高pCR率。
方法
回顾了2009年4月至2011年12月期间接受卡铂、紫杉烷和曲妥珠单抗（HER2阳性疾病）治疗的患者的肿瘤特征、pCR率（乳腺和淋巴结无浸润性疾病）、毒性和生存率。
结果
38例患者（39个肿瘤）完成了中位4周期的新辅助化疗。39个肿瘤中有18个（46%）为HER2阳性，18个中的8个（44%）达到pCR；18个HER2阳性肿瘤中有13个（72%）为激素受体（HR）阳性，其中4个（31%）达到pCR。39个肿瘤中有10个（26%）为TNBC；10个中的6个（60%）达到pCR。在中位25个月时，pCR患者未观察到复发。
结论
对于HER2阳性和TNBC的局部晚期乳腺癌（LABC）患者，有必要进行不含蒽环类药物的含铂新辅助化疗的前瞻性研究。
相似文献
1
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.在接受含或不含曲妥珠单抗的卡铂和紫杉醇无蒽环类新辅助化疗后，三阴性、HER2阳性和激素受体阳性乳腺癌的病理完全缓解率。
Breast. 2015 Feb;24(1):18-23. doi: 10.1016/j.breast.2014.10.008. Epub 2014 Nov 20.
2
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.三阴性乳腺癌对多西他赛和卡铂为基础的新辅助治疗的差异性反应。
Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.
3
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].卡铂联合紫杉醇新辅助治疗局部晚期三阴性乳腺癌的II期临床试验
Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011.
4
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.TP53突变在接受新辅助蒽环类/紫杉类化疗的三阴性和HER2阳性乳腺癌中的作用。
Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.
5
Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.多西他赛、卡铂和曲妥珠单抗新辅助治疗HER2阳性局部晚期和寡转移性乳腺癌的疗效与安全性回顾性研究：一项印度经验
Indian J Cancer. 2017 Jan-Mar;54(1):343-346. doi: 10.4103/ijc.IJC_152_17.
6
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.每4周使用卡铂联合每周使用紫杉醇（加或不加曲妥珠单抗）治疗侵袭性II至III期乳腺癌时频繁出现病理完全缓解：布朗大学肿瘤学组研究
J Clin Oncol. 2009 Oct 1;27(28):4693-700. doi: 10.1200/JCO.2008.21.4163. Epub 2009 Aug 31.
7
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.新辅助每周一次纳米白蛋白结合型紫杉醇、卡铂及每两周一次贝伐单抗治疗临床II期或III期HER2阴性乳腺癌女性的II期试验
Clin Breast Cancer. 2014 Aug;14(4):228-34. doi: 10.1016/j.clbc.2014.02.005. Epub 2014 Feb 20.
8
Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.无蒽环类新辅助化疗可确保乳腺癌更高的病理完全缓解率。
Clin Breast Cancer. 2017 Feb;17(1):34-40. doi: 10.1016/j.clbc.2016.06.010. Epub 2016 Jun 25.
9
10
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.Ⅱ期研究：新辅助每周紫杉醇联合白蛋白结合型紫杉醇和卡铂，联合贝伐珠单抗和曲妥珠单抗，用于治疗局部晚期 HER2+ 乳腺癌女性患者。
Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5.
引用本文的文献
1
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012).用于预测乳腺癌患者新辅助化疗后病理淋巴结阴性的列线图：一项全国性、多中心回顾性队列研究（CSBrS-012）。
Front Oncol. 2024 May 10;14:1326385. doi: 10.3389/fonc.2024.1326385. eCollection 2024.
2
Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients.确定预测抗 HER2 治疗反应的因素在 HER2 阳性乳腺癌患者中的应用。
Cancer Control. 2023 Jan-Dec;30:10732748221141672. doi: 10.1177/10732748221141672.
3
The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data.新辅助化疗后ypN0的cT1-2N1乳腺癌患者术后放疗的影响：一项基于真实世界数据的回顾性研究
Discov Oncol. 2023 Jan 7;14(1):2. doi: 10.1007/s12672-022-00609-8.
4
Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis.曲妥珠单抗治疗人表皮生长因子受体-2 阳性乳腺癌：系统评价和荟萃分析
BJS Open. 2022 May 2;6(3). doi: 10.1093/bjsopen/zrac028.
5
Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.顺铂或卡铂新辅助化疗后三阴性乳腺癌的病理完全缓解：一项系统评价和荟萃分析。
Exp Ther Med. 2022 Jan;23(1):91. doi: 10.3892/etm.2021.11014. Epub 2021 Nov 26.
6
Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer.新辅助紫杉烷和卡铂联合抗HER2靶向治疗HER2阳性乳腺癌的最佳疗程
Front Oncol. 2021 Jun 8;11:686591. doi: 10.3389/fonc.2021.686591. eCollection 2021.
7
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data.帕妥珠单抗与曲妥珠单抗联合治疗HER2阳性早期乳腺癌：新出现临床数据综述
Breast Cancer (Dove Med Press). 2021 Jun 14;13:393-407. doi: 10.2147/BCTT.S176514. eCollection 2021.
8
Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.伴有BRCA2基因新型变异的同步性卵巢癌和乳腺癌：一例报告
Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
9
Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis.化疗诱导乳腺癌干细胞特性与单核细胞失调相关。
Clin Cancer Res. 2018 May 15;24(10):2370-2382. doi: 10.1158/1078-0432.CCR-17-2545. Epub 2018 Mar 2.
10
Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.多西他赛、卡铂联合每周一次曲妥珠单抗的新辅助化疗对HER2阳性早期乳腺癌有效：中位随访4年以上的结果
Breast Care (Basel). 2016 Oct;11(5):323-327. doi: 10.1159/000452079. Epub 2016 Oct 24.
本文引用的文献
1
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.吉西他滨、卡铂和依尼帕利作为三阴性及BRCA1/2突变相关乳腺癌新辅助治疗的II期研究，并评估基于肿瘤的基因组不稳定性指标：PrECOG 0105。
J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.
2
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.拉帕替尼联合曲妥珠单抗治疗人表皮生长因子受体 2 阳性早期乳腺癌（NeoALTTO）：一项随机、开放标签、多中心、III 期临床试验的生存结果及其与病理完全缓解的关系。
Lancet Oncol. 2014 Sep;15(10):1137-46. doi: 10.1016/S1470-2045(14)70320-1. Epub 2014 Aug 14.
3
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).在II至III期三阴性乳腺癌中，于每周一次的新辅助紫杉醇治疗后加用卡铂和/或贝伐单抗，随后进行剂量密集型阿霉素和环磷酰胺治疗，对病理完全缓解率的影响：CALGB 40603（联盟）研究
J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.
4
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助和辅助治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌（NOAH）患者：一项随机对照优效试验的随访，该试验具有平行的人表皮生长因子受体 2 阴性队列。
Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.
5
The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.铂类药物作为三阴性乳腺癌新辅助化疗的价值：一项系统评价和荟萃分析。
Breast Cancer Res Treat. 2014 Apr;144(2):223-32. doi: 10.1007/s10549-014-2876-z. Epub 2014 Feb 21.
6
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.拉帕替尼作为曲妥珠单抗辅助治疗 HER2 阳性可手术乳腺癌的新辅助治疗（NSABP 协议 B-41）：一项开放标签、随机、3 期临床试验。
Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.
7
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.标准新辅助化疗后残余三阴性乳腺癌的功能蛋白质组学特征分析。
Ann Oncol. 2013 Oct;24(10):2522-2526. doi: 10.1093/annonc/mdt248. Epub 2013 Aug 7.
8
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.早期乳腺癌的分子亚型鉴定出一组不能从新辅助化疗中获益的患者。
Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. Epub 2013 Jun 12.
9
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).曲妥珠单抗联合帕妥珠单抗与标准新辅助含蒽环类和不含蒽环类化疗方案联合用于人表皮生长因子受体 2 阳性早期乳腺癌患者：一项随机 II 期心脏安全性研究（TRYPHAENA）。
Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22.
10
Neoadjuvant treatment of breast cancer.乳腺癌的新辅助治疗。
Ann Oncol. 2012 Sep;23 Suppl 10(Suppl 10):x231-6. doi: 10.1093/annonc/mds324.
Zotero 插件